Introduction
In recent years both the development of capillary networks, as well as the development of collateral conductance arteries was referred to as angiogenesis. However, the term angiogenesis is now reserved for the process of formation of new capillary networks via sprouting of endothelial cells, whereas the term arteriogenesis is used to describe the proliferation of pre-existing arteriolar connections into functional collateral arteries upon narrowing of a main artery '" 4 . The pre-existing nature of these collateral arteriolar connections as well as their transformation into larger conductance arteries upon arterial obstruction has been recognized for a long time 5 " 8 .
Arteriogenesis, in contrast to angiogenesis, is independent of ischemia and is thought to be shear stress induced ' . The involvement of monocytes during arteriogenesis became evident in recent years. Already in 1975 it was noted that monocytes adhere to the endothelium of growing collateral arteries ". In subsequent studies it was shown that these cells transmigrate through the endothelium of these vessels, accumulate as macrophages in the perivascular space and produce locally factors like Tumor Necrosis Factor alpha (TNF-a ), basic Fibroblast Growth Factor (bFGF) and PR39 l2 " 14 . In a previous study we showed that the attraction of monocytes to proliferating collateral arteries by exogenously applied Monocyte Chemoattractant Protein-1 (MCP-1) strongly increases the arteriogenic response upon femoral artery ligation in the rabbit hindlimb l5 .
Transforming Growth Factor-beta 1 (TGF-6|) was found in non-ischemic areas of collateral vessel development both in experimental as well as in clinical settings l6 ' 17 suggesting a modulating role of this growth factor during arteriogenesis. TGF-B| was also reported to be chemoattractive for circulating monocytes, the key mediators in arteriogenesis l8 ' 19 . Furthermore, TGF-B| induces the expression of various growth factors by these cells * . However, the influence of TGF-B, on monocyte adhesion and their subsequent migration, decisive steps in the process of arteriogenesis, is unclear. Moreover, the in-vivo effects of exogenously applied TGF-8, on arteriogenesis are not known.
We hypothesized that TGF-B| positively modulates arteriogenesis in-vivo. Therefore we studied the expression of TGF-6, in a model of arteriogenesis in the rabbit hindlimb. In this model the femoral artery is ligated, leaving all side branches intact. Under resting conditions no ischemia occurs 2I . Angiogenesis, is only observed in the lower limb, distant from the site of arteriogenesis and is probably induced by repetitive ischemia in the lower leg during physical activity 9 . Using this model we established the effects of exogenously applied TGF-Bi on the process of arteriogenesis. In addition, we studied the effects of TGF-B| on monocyte adhesion and trans-endothelial migration in-vitro . To the best of our knowledge this is the first report of an experimental therapeutic approach to stimulate arteriogenesis using TGF-13,.
Methods

In-vivo experiments
Animal model
The present study was performed with the permission of the State of Hessen, Regierungspraesidium Darmstadt, according to Section 8 of the German Law for the Protection of Animals. It conforms to the "Guide for the Care and Use of Laborator)' Animals " (NIH Publication No. 85-23, revised 1996). 36 New Zealand White Rabbits (NZWR) were randomly assigned to one of three groups (n=12 each). In two groups the femoral artery was ligated and either Phosphate Buffered Saline (PBS) or TGF-B, (0.48 ug/kg/d) (PeproTech) was delivered locally, directly into the collateral circulation, via an osmotic minipump as previously described 22 . The third group was evaluated without ligation to obtain the normal conductance value and angiographic appearance of the vascular tree of the rabbit hindlimb. For final experiments, animals of each group were randomly assigned to either angiographic or hemodynamic measurements.
Post-mortem angiograms X-ray angiograms were performed as previously described . Following Longland*s definition, only vessels showing a defined slem, midzone and re-entry, identifying them as collateral arteries, were counted .
Hemodynamic measurements Hemodynamic measurements and calculations of collateral conductance were performed as previously described 22 . In brief, after the treatment period animals were anesthetized, heparinized and a pump-driven, flow controlled shunt between the carotid artery and the distal abdominal aorta was installed. Six differently labeled fluorescent microspheres (diameter 15 urn; Molecular Probes) were injected into the shunt system, each at a different pressure level. To guarantee maximum vasodilatation, adenosine was continuously infused at a rate of I mg/kg/min. Peripheral and systemic pressures as well as total flow were measured and archived via a computer-based recording system (MacLab, Macintosh). A reference sample was withdrawn at each pressure level. After digestion of muscle tissue samples and FACS-analysis for counting of microspheres, collateral conductance was calculated from the slope of the flow/pressure relations.
Immunohistochemistry
An additional six animals were operated as described above and treated with either PBS (n=3) or TGF-B| (n=3). Three days after ligation of the femoral artery, animals were sacrificed and tissue was harvested from the hindlimb muscles for histological examination. For immunohistochemistry, frozen sections (10 m thick) were placed on gelatine-coated slides and fixed for 10 min in 4% paraformaldehyde. Tissue sections were exposed for 10 min in 0.1% carboxylated bovine serum albumin (Aurion) in PBS. followed by incubation for 2 hours at room temperature (RT) with the primary monoclonal antibodies against alpha-smooth muscle actin (directly The measurements of immunofluorescence intensity were performed using confocal microscopy as described elsewhere """' and applied previously to protein measurements in a dog model of coronary collateral arteriogenesis 24 . The fluorescence intensity of TGF-6) was measured in at least three growing arteries at 5 different serial levels for each animal and was expressed as arbitrary units per urn 2 vascular wall. Vascular cell proliferation rates were quantified as percent of Ki-67 positive cells per total number of smooth muscle cells and per total number of endoluminal cells in 5 serial sections taken at 100 pm intervals. CD31-positive capillaries were counted only in transversally sectioned tissue, derived from the peripheral hindlimb musculature, and were expressed as number of capillaries/mm 2 .
Western blotting
Total protein was prepared from collateral arteries of rabbits (n = 6) subjected to either three days of femoral artery ligation or sham operation. Frozen collateral vessels containing small remaining parts of the surrounding quadriceps vastus intermedins muscle were placed in protein extraction buffer (50 mM Tris/HCl at pH 7.4, 250 mM sucrose, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton, I mM DTT, 0.5 mM PMSF) and homogenized by 50 strokes in an icecold Dounce homogenizer. The lysates were centrifuged at 15000 x g at 4°C for 30 minutes. Both 1 ug of monoclonal anti-TGF-B| antibody (R&D Systems) and 30 pi of ProteinA-Sepharose (Santa Cruz Biotechnology) were supplied to 200 pg of protein extracts and incubated on a rotating wheel at 4°C over night. The precipitates were washed twice with TNET buffer (50 mM Tris/HCl, 140 mM NaCl, 5 mM EDTA, 1% Triton-X 100), TNE buffer (50 mM Tris/HCl, 140 mM NaCl, 5 mM EDTA) and distilled water and subsequently resuspended in 4x LDS sample buffer (Novex) supplemented with p-mercaptoethanol to an end-concentration of 4.7 M. After boiling for 10 minutes the samples were separated by using 4-12% Bis-Tris gels (Novex) and the gel electrophoresis was performed under reducing conditions. Following protein transfer to a nitrocellulose membrane (Novex), non specific binding was blocked by incubation with 3% bovine serum albumine in TBST (10 mM Tris pH 8.0, 150 mM NaCl 0.05% Tween 20) for 2 hours at room temperature (RT). The incubation with the primary antibody (dilution 1:500) occurred over night at 4°C, followed by incubation with the secondary antibody for 2-3 hours at room temperature. Detection of immuno-reactive bands was performed with an ECL-system (Amersham Pharmacia Biotech). Optical density was measured using J Image software (available on the internet as shareware).
ln-vitro experiments
Monocyte and endothelial cell preparation Monocytes were isolated from buffy coats of healthy blood donors by density gradient centri(ligation and elutriation as described previously . Human umbilical vein endothelial cells (HUVECs) were prepared according to the method of Jaffe et al. and were cultivated as described elsewhere .
Adhesion assay
Adhesion assays were performed as previously described 2? . Monocytes were stimulated for two hours with TGF-I3| (concentrations; 0.1 to 10.000 pg/ml) (PeproTech) or LPS (positive control). To identify the effects of TGF-B, stimulation of endothelial cells on the adhesion of monocytes, HUVECs were either stimulated with TNF-a (positive control, 10 ng/ml, obtained from Sigma) or with different doses of TGF-fi|.
Transmigration assay
Transmigration assays were performed as previously described "" to test the chemoattractive potency of TGF-B| over a layer of endothelial cells. Concentrations of 0.1 to 10.000 pg/ml TGF-B] were used. In a second set of transmigration assays the influence of monocyte-stimulation and/or endothelium-stimulation with TGF-B, was determined.
Expression of adhesion molecules on monocytes and endothelial cells
HUVECs were stimulated with either TNF-a (positive control) or TGF-B,. Nonstimulated HUVECs served as a negative control. To quantify expression of cell adhesion molecules, cells were stained with a fluorochrome-conjugatcd monoclonal antibody against ICAM-1, VCAM or P-selectin (Dianova) after the different treatments. To quantify the effect of TGF-B, on the expression of monocyte Mac-1, isolated human monocytes were treated with different doses of TGF-B,. Mac-1 expression was quantified using FITC-conjugated monoclonal antibodies against CD1 lb and CD 18 (Dianova). CD1 lb expression on rabbit cells was performed in whole blood by an indirect staining protocol using a monoclonal antibody against rabbit CD 1 lb and a FITC-conjugated anti mouse IgG antibody (both from Dianova).
Angiogenesis spheroid model
In vitro angiogenesis in collagen gels was quantitated using spheroids of macrovascular endothelial cells as described previously 27 ' 28 . In brief, HUVEC spheroids containing -750 cells were generated overnight after which they were embedded into collagen gels. A collagen stock solution was prepared prior to use by mixing 8 vol acidic collagen extract of rat tails (equilibrated to 3 mg/ml, 4°C) with 1 vol 10x EBSS (Gibco-BRL) and -1 vol 0.1 N NaOH to adjust the pH to 7.4. This stock, solution (0.5 ml) was mixed with 0.5 ml room temperature (rt) ECGM basal medium (PromoCell) containing 40% FCS (Biochrom), 1.2% (v/w) methylcellulosc (4.000cpi; Sigma), 50 HUVEC spheroids, and the corresponding test substances VEGF and TGFB| (R&D Systems). TGFB, was applied in dosages ranging from 0,1 till 10 ng/ml. The spheroid-containing gel was rapidly transferred into 24 well plates and allowed to polymerize (1 min) after which 0.15 ml ECGM basal medium (Promocell) was pipetted on top of the gel. The gels were incubated at 37°C, 5% C02 and 100% humidity. After 3 days, in vitro angiogenesis was digitally quantitated by measuring the cumulative length of the sprouts that had grown out of each spheroid using digital imaging software DP-Soft (Olympus) analyzing at least 10 spheroids per experimental group and experiment.
Statistical Analysis
Results are presented as mean ± standard deviation. Significant differences between sample means were determined with an independent-samples T-test. Differences with a p-value < 0.05 were classified as significant.
Results ln-vivo effects of TGF-fii on arteriogenesis
No animals were lost during or after femoral artery ligation. No gross impairment of hindlimb function was observed after femoral artery occlusion. The body weights and body temperature within the different groups did not show any significant difference. There were no detectable differences in the values of total protein, albumin, glutamic oxaloacetic transaminase and glutamic pyruvic transaminase.
Histological findings TGF-I3| in control sections of the non-occluded hindlimbs could rarely be detected. Three days after ligation of the femoral artery, TGF-B, was detected immunohistochemically within and around growing collateral arteries, as well as in infiltrating cells ( figure 1A) . In TGF-B, treated animals, TGF-B, immunolabeling was dramatically increased as compared to the control-animals (figure IB). Quantitative immunofluoresecence of TGF-B, immunolabeling revealed a statistical difference (pO.001) in the values of the quantity of TGF-B, per unit arterial surface area in TGF-B, treated animals (140.8 ±13.1 arbitrary units/urn 2 ) as compared with PBS treated animals (33.3 ± 13.1 arbitrary units/pm 2 ), confirming delivery of the substance. Three days after femoral artery ligation the number of proliferating vascular smooth muscle cells was significantly higher in the TGF-B| treated animals (control 2.65 ± 0.90%, vs. TGF-B, 5.85 ±1.11%, pO.01). 
Angiographic findings
Angiograms performed one week after ligation of the femoral artery showed several, typically corkscrewed, collateral arteries spanning from the arteria profunda femoris and the arteria circumflexa femoris to the arteria genualis and the arteria saphena parva (figure 4a). TGF-B| infusion for a time-period of one week significantly increased the number of visible collateral arteries as compared to the PBS-conlrol group (figure 4b and 5) (PBS; 15.2 ± 3.4, TGF-B,; 24.6 ± 4.1. p< 0.05).
Haemodynamic parameters
One week after femoral artery ligation, collateral conductance in the control group was 4.1 ± 0.5 ml/min/lOOmmHg. TGF-B, had significantly increased collateral conductance to over 7-fold as compared to the PBS-treated group (28.9 ± 3.7 ml/min/lOOmmHg, figure 6 ). In the non-occluded control group a conductance value of 161.5 ± 10.8 ml/min/lOOmmHg was measured.
In-v itro effects of TGF-B i on monocyte adhesion and transendothelial migration Monocyte stimulation Adhesion assay A strongly increased adhesion to the HUVEC layer was observed after stimulation of monocytes with TGF-Bi. The adhesion of monocytes was linearly related to TGF-B| dose ( figure 7) . The maximally achieved adhesion of monocytes upon TGF-Bi treatment was similar to the adhesion observed for the positive control (LPS: 120.2 ± 8.3 cells/field vs. TGF-B,: 114.0 ± 4.7, p=NS).
FACS-analysis of MAC-1 expression
The expression of the MAC-1 receptor significantly increased, dose-dependently, after stimulation of human monocytes with TGF-B, (figure 8 
Endothelial cell stimulation
The treatment of the HUVECs layer with TGF-B, caused no increase in the number of adhered monocytes as compared to the control. This was confirmed by F ACS analysis, showing no significant increase in the expression of cell adhesion molecules on endothelial cells treated with TGF-B] (figure 9).
Effects of TGF-B, on trans-endothelial migration of monocytes
Transmigration assay TGF-B, showed no chemoattractive potency towards monocytes in the transendothelial migration assays. When TGF-B, was diluted into the lower chamber of the assay at different concentrations ranging from 0.1 pg/ml to 10 ng/ml, the migration of monocytes did not differ significantly from the control assay and was significantly lower as compared to MCP-1 (control: 2.01 ±0.31,0.1 pg/ml: 1,76 ± 0.43, TGF-B, 1 pg/ml: 1.51 ±0.39, TGF-B, 10 pg/ml: 1.47 ± 0.41, TGF-B, 100 pg/ml: 2.37 ±0.65, TGF-B, 1 ng/ml: 1.55 ± 0.35, TGF-B, 10 ng/ml: 1.56 ±0.27, TGF-B,, MCP-1 1 ng/ml: 5.84 ±0,48 * 10 5 monocytes/ml).
Also when the HUVEC-layer was stimulated with TGF-B,, no increase in the number of transmigrated cells was observed. However, when monocytes were prestimulated with TGF-B, an increased trans-endothelial migration of monocytes was observed as compared to the control group. When monocytes and endothelium were stimulated simultaneously with TGF-B| the transmigration rate was similar to that after monocyte stimulation alone. Maximum migration of monocytes was achieved when MCP-1 was added to the lower chamber of the transmigration assay, in combination with TGF-B, stimulation of monocytes (figure 10).
119
Angiogenesis spheroid model EC spheroids have a low baseline sprouting activity which can be strongly stimulated by exogenous VEGF(50 ng/ml). There was no significant sprouting originating from TGF-B, pretreated spheroids (24h, 5ng/ml) or alter stimulation with TGF-B| in a range of doses from 0.1 to 10 ng/ml (data not shown. TGF-B, pretreated spheroids showed a significant inhibition of VEGF mediated sprouting (p<0.001)(figure 11). . This is also stressed by the differential effects of the angiogenic factor VEGF and the angiogenic/arteriogenic factor b-FGF as shown elegantly in different experimental settings " ,1~33
Discussion
. The rabbit hindlimb model of femoral artery occlusion is an excellent model to study arteriogenesis specifically. After the occlusion of the femoral artery, pre-existing interconnecting arterioles, spanning from the arteria profunda femoris and the arteria circumflexa femoris to the arteria genualis and the arteria saphena parva, are recruited. These collateral arteries develop in a non-ischemic environment 2 '. The mechanism of induction of vessel growth in this model is the elevated shear stress in the preexisting collateral arterioles. Although this model is non-ischemic at rest, angiogenesis can be observed, probably due to repetitive ischemia during physical activity. However, the amount of new capillaries is small and angiogenesis is limited to the peripheral hindlimb at sites distant from the region of arteriogenesis 9 .
TGF-fii and arteriogenesis TGF-B is secreted from cells as a latent precursor molecule of 55 kDa. Soon after secretion the precursor is proteolytically cleaved to produce mature TGF-B that is inactive as it still remains non-covalently bound to the latency-associated peptide 34 . This latent TGF-B complex is bound to microfibrillar structures of the extracellular matrix, where it can be released and activated by proteolysis 35 . The active 25 kDa homodimeric TGF-B| molecule consists of two identical disulfide-linkcd 12.5 kDA polypeptide chains 36 .
It was shown in the porcine heart that the expression of TGF-B, is strongly increased in the non-infarcted area at risk l6 . In rats, after occlusion of the left coronary artery, an increased expression of TGF-B, was noted in the non-infarcted interventricular septum, a known predilection site for growth of coronary collateral arteries 3/ . Such increased expression of TGF-B, was also observed in the border zone of infarcts in the human brain ''. This increased expression in regions adjacent to infarctcd areas TGF-B 1 STIMULATES ARTERIOGENESIS suggests a possible role for TGF-B, in the restoration of blood How after arterial obstruction. With both immuno-histochemistry as well as Western blot analysis we show that in the non-ischemic model of femoral artery ligation in the rabbit hindlimb, TGF-B| is also abundantly present around the growing collateral arteries. Interestingly, using Northern blot analysis, no increase in mRNA transcription for TGF-B| was found (data not shown). However, no deductions as to the change in transcriptional activity can be made from mRNA tissue concentrations which may not reilect RNA turnover. Staining for TGF-B, in rabbit hindlimbs after femoral artery ligation was only positive around growing collateral arteries that also expressed the proliferation marker Ki-67. TGF-B, was detectable not only in the extra-cellular space of adventitial cells but was also expressed by infiltrating cells. This TGF-B| expression during arteriogenesis is not dependent on the presence of ischemia (growing collaterals are surrounded by normoxic tissue and they are perfused by arterial blood) but may be dependent on increased shear stress as reported earlier " . Interestingly, another mechanical force, cyclic stretch, can also upregulate TGF-B, 39 . X-ray angiograms of TGF-B!-treated animals showed a higher number of visible collateral vessels (i.e. vessels with a diameter larger than 50 urn). However, angiographic parameters not always correlate well with perfusion . Therefore more importantly, TGF-B, increased the conductance of the collateral circulation about seven-fold, one week after femoral artery ligation. Conductance represents the maximal capacity of the collateral circulation and is the most direct quantitative measurement of collateral artery growth.
TGF-fii and monocytes
Wiseman reported maximal chemoattractive activity at concentrations ranging from 0.1 to 1 pg/ml and monocyte activation at concentrations of 10 to 100 pg/ml . These data are confirmed in part by our own experiments that showed monocyte activation (i.e. increased adhesion) at higher doses. However, the reported chemotactic activity of TGF-B) towards monocytes was not reproducible over a layer of endothelial cells in a wide range of dosages. The chemo-attractivc activity of TGF-B, was reported from experiments with regular chemotaxis chambers ' , without an endothelial layer. This suggests that other factors than chemo-attractive activity alone are decisive for the number of transmigrated cells in the transendothelial migration assay. In contrast to the absence of chemo-attractive activity of TGF-B,, a strong increase in adhesion to endothelial cells was observed for TGF-B, stimulated monocytes. Moreover, this led to an increase in the number of trans-endothelial migrated monocytes. The results of the adhesion and transmigration assays correlated with data from FACS-analysis showing that TGF-B, leads to an increase of the expression of monocytic adhesion receptor MAC-1. These data suggest a role for this receptor in the observed TGF-B, effect on arteriogenesis. Currently we are performing experiments using specific MAC-1 antibodies and MAC-1 knockout mice for more definite proof of this concept. This confirms data reponed earlier by Pepper et al and stresses the notion that the invitro angiogenic effects of TGF-B, depend strongly on the experimental setting 48 . In our in-vivo model we also observed no influence on angiogenesis by TGF-B]. It should be noted however that the used in-vivo model was not designed to study angiogenesis but merely to study arteriogenesis.
In our in-vivo setting of arteriogenesis, inhibition of endothelial cell proliferation is probably compensated for by the mechanisms of increased monocyte activation, adhesion and transmigration and the subsequent release of vascular growth factors. A second explanation for the seemingly paradoxical arteriogenic effect of TGF-B] is the fact that the process of arteriogenesis, in contrast to angiogenesis, consists mainly of proliferation of smooth muscle cells. Therefore it is of notice that TGF-B| induces vascular smooth muscle cell proliferation via PDGF 49 ' 50 .
Angiogenesis, Arteriogenesis and Atherosclerosis
Epstein recently highlighted the several potential negative side-effects that need special attention when applying strategies trying to stimulate collateral vessel growth . One of these potential side-effects is the induction or amelioration of atherosclerosis. The role of TGF-B] in atherosclerosis is controversially discussed 5 ' 1 . For example Big-h3, a TGF-B, -inducible gene was found to be overexpressed in 122 TGF-B1 STIMULATES ARTERIOGENESIS human atherosclerotic and restenotic lesions, suggesting a promoting role of TGF-B, in atherogenesis 58 . In contrast, Grainger et al. could show that serum concentrations of active TGF-B, were severely depressed in advanced atherosclerosis. Patients with triple vessel disease showed a marked decrease of the active form of TGF-6| to levels less than 25% as compared to patients with chest pain, showing normal coronary angiograms 52 . These data suggest that the active form of TGF-B, has antiatherogenic effects. This was confirmed by studies in ApoE mice, showing that the anti-atherogenic properties of both Tamoxifen and anti-CD40L are associated with increased levels of active TGF-B, 59 ,6°. More recently it was shown that TGF-B, promotes lipid-cfflux from macrophages, offering a mechanistic explanation for its anti-atherogenic properties 6I .
Conclusion
To the best of our knowledge, the present report describes for the first time TGF-B, as a specific pro-arteriogenic substance. Increased levels of immuno-rcactive TGF-B| in growing collateral arteries after femoral artery ligation were shown in a rabbit model of femoral artery ligation. This confirms earlier reports, suggesting a possible stimulatory role for TGF-B, in the natural process of arteriogenesis. In vivo, a strong arteriogenic effect was found upon exogenous application of TGF-B, after femoral artery ligation. The number of collateral arteries on the x-ray angiograms as well as the conductance of the collateral vessels showed a significant increase upon TGF-B, treatment. It has been described by other authors that TGF-B, induces the expression of several growth factors by monocytes/macrophages. This offers an explanation for the observed arteriogenic effects of TGF-B,. In addition, as another mechanistic explanation for the arteriogenic effects of TGF-B,, we show that TGF-B| induces MAC-1 receptor expression and increases monocytic adhesion and trans-endothelial migration, necessary steps during arteriogenesis. Further studies, using specific MAC-1 antibodies and MAC-1 knockout mice, are on the way to provide in-vivo data on the role of the MAC-1 receptor during arteriogenesis. 
